Upstream Bio Q3 2026 Results: Net Loss of $41.2M, Loss Widens
Upstream Bio reported a net loss of $121.5 million for the nine months ended September 30, 2026, compared to $101.0 million in the prior year, driven primarily by increased research and development expenses for its lead candidate, verekitug. The company's cash, cash equivalents, and short-term investments totaled $207.4 million as of September 30, 2026, down from $341.5 million at the end of 2025.
- Key figure
- Net loss $41.2M